Related Experiment Video
Updated: May 20, 2026

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
Published on: April 19, 2024
Comment on "Meta-Analysis of Cost-Effectiveness" by Bang and Zhao: Combinability, Joint Modeling, and a Two-Stage
Gian Luca Di Tanna1, Niklaus Meier2, Matthias Schwenkglenks3
1University of Applied Sciences and Arts of Southern Switzerland - SUPSI, Lugano, Switzerland.
None:
Bang and Zhao address an important methodological gap by proposing meta-analytic methods for cost-effectiveness analysis (CEA) based on separate pooling of incremental costs (ΔC) and incremental effectiveness (ΔE), with summaries displayed on the cost-effectiveness plane. We share the aim of expanding the toolkit for CEA synthesis; however, we believe that several issues need clarification before the proposal can serve as a general blueprint. First, the two motivating examples appear not to satisfy the key combinability criteria described by Shields and Elvidge. Second, the proposal does not incorporate the data harmonization steps recommended for the meta-analysis of economic evaluations by Bagepally et al. Third, separate univariate pooling does not retain the within-study association between ΔC and ΔE, which complicates the joint interpretation of the pooled ICER and its uncertainty. As a possible way forward, we propose a two-stage framework in which a structured combinability assessment and data harmonization precede any quantitative synthesis, and discuss why joint modeling of (ΔC, ΔE) is preferable to separate univariate pooling. In our view, such a framework provides a more defensible route to pooled ICERs, joint uncertainty summaries, and decision-relevant quantities such as cost-effectiveness acceptability curves (CEACs).
Related Concept Videos
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
